---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262780795.md"
description: "Novartis AG agreed to acquire the American biotechnology company Avidity Biosciences for $72 per share, representing a premium of 46%, with a transaction valuation of $12 billion. This move will strengthen its late-stage neuroscience research and development pipeline"
datetime: "2025-10-26T17:04:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262780795.md)
  - [en](https://longbridge.com/en/news/262780795.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262780795.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/262780795.md) | [繁體中文](https://longbridge.com/zh-HK/news/262780795.md)


# 

Novartis AG has agreed to acquire the American biotechnology company Avidity Biosciences for $72 per share, representing a premium of 46%, with a transaction valuation of $12 billion. This move will strengthen its late-stage neuroscience research and development pipeline

### Related Stocks

- [Novartis AG (NVS.US)](https://longbridge.com/en/quote/NVS.US.md)

## Related News & Research

- [Novartis Agrees To Acquire Excellergy, Inc.](https://longbridge.com/en/news/280735969.md)
- [Teva Pharmaceutical Gets US FDA Approval for Prolia Biosimilar; Xoliar Biosimiliar Applications Accepted in US, Europe](https://longbridge.com/en/news/281026919.md)
- [This stock popped 15% in its trading debut. Meet Quantum’s new kid on the block.](https://longbridge.com/en/news/281082698.md)
- [NHS clears Wegovy to reduce risk of heart attack and stroke](https://longbridge.com/en/news/281323250.md)
- [Norfolk Southern Earnings Preview: What to Expect](https://longbridge.com/en/news/280999046.md)